Thermo Fisher Scientific at ESMO 2017 Congress
Thermo Fisher Scientific Symposium
Next-generation sequencing and Oncomine solutions are advancing precision oncology research enabling multi biomarker testing on limited material extracted from FFPE samples.
See what thoughts leaders have presented during "Next-generation sequencing—driving precision oncology research" symposium. From automated data analysis and reporting to an international multi-centre study using a NGS for liquid biopsy analysis. You will also learn about the newest NGS technologies, to study immune system response to cancer.
Download what they have presented.
|Oncomine Knowledgebase Reporter - Processing the NGS data for you
Managing, and ultimately interpreting, data produced by NGS in oncology presents a challenge. In her talk Isabelle will share her experience with NGS analysis of FFPE solid tumour tissue using Ion Torrent™ Oncomine™ Focus Assay (52 target genes) and Ion Torrent™ Oncomine™ Knowledge Base Report software. The software processes the data down to only relevant variant result, linking it with to drug labels, treatment guidelines, and open clinical trials, enabling the laboratory to provide clear and useful report.
|Advancing lung liquid biopsy research with NGS
Tumour-specific mutations in plasma can serve as biomarkers for tumour detection, monitoring tumour response to therapies, detecting residual disease, and enabling long-term follow-up. Dr Normanno will present the results of an international multi-centre study using a NGS liquid biopsy assay. He will also discuss how this new workflow may enable in the future better understanding of tumour evolution during treatment or how to use research findings to inform anticipatory second- or third-line therapy according to the molecular evolution of residual disease.
|Immune profiling of genetic instability in colorectal cancer
Immunotherapy, based on immune checkpoint inhibitors, is being routinely used in several types of cancer, including melanoma and lung cancer. In other models, such as colorectal cancer, gastric cancer and bladder cancer, advanced stage clinical trials show very promising results. Although effective, not every patient benefits from this type of treatment. Response to immunotherapy is likely to be dependent on more variables than immune checkpoint proteins expression alone and multiple biomarker approach is likely going to be necessary to deliver truly personalised treatment solutions. Prof. Jose Carlos Machado will discuss other approaches how, using the newest next-generation sequencing (NGS) technologies, to study immune system response to cancer development and establish more efficient biomarkers and biomarker signatures.